Cargando…

Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height

PURPOSE: The aim of this study was to analyze regression rates and local control of uveal melanoma patients treated with iodine-125 ((125)I) brachytherapy based on initial tumor apical height. MATERIAL AND METHODS: Patients treated in a single institution from January 1(st), 1996 to 2019 with (125)I...

Descripción completa

Detalles Bibliográficos
Autores principales: Miguel, David, Saornil, María Antonia, de Frutos, Jesús María, García-Álvarez, Ciro, Alonso, Pilar, Diezhandino, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060957/
https://www.ncbi.nlm.nih.gov/pubmed/33897784
http://dx.doi.org/10.5114/jcb.2021.105278
_version_ 1783681467059011584
author Miguel, David
Saornil, María Antonia
de Frutos, Jesús María
García-Álvarez, Ciro
Alonso, Pilar
Diezhandino, Patricia
author_facet Miguel, David
Saornil, María Antonia
de Frutos, Jesús María
García-Álvarez, Ciro
Alonso, Pilar
Diezhandino, Patricia
author_sort Miguel, David
collection PubMed
description PURPOSE: The aim of this study was to analyze regression rates and local control of uveal melanoma patients treated with iodine-125 ((125)I) brachytherapy based on initial tumor apical height. MATERIAL AND METHODS: Patients treated in a single institution from January 1(st), 1996 to 2019 with (125)I plaques (ROPES and COMS) for uveal melanoma were included in this study. Patients treated with brachytherapy for iris and those treated with transpupillary thermotherapy prior to brachytherapy were excluded. The sample was classified into 4 categories depending on initial apical tumor height (h(0)), i.e., h(0) ≤ 2.5 (small), 2.5 < h(0) ≤ 6.25 (small-medium), 6.25 < h(0) ≤ 10 (medium-large), and h(0) > 10 mm (large). Percentage of original tumor apical height (Δh) was collected during follow-ups. Patterns of regression were evaluated using linear least squares adjustments. Multivariable Cox regression were performed. RESULTS: In total, 305 patients met the inclusion criteria, and 27, 166, 100, and 13 were considered for small, small-medium, medium-large, and large categories, respectively. Median follow-up was 82.4, 56.8, 76.1, 89.1, and 100.1 months for the entire cohort and each sub-group, respectively. Pattern of decrease when h(0) ≤ 2.5 mm was not detectable. For the rest sub-groups, changes in height could be fitted using functional form: Δh (T) = ae(–bT) + c, R(2) ≥ 0.97. Multivariate Cox analysis factors predictive of local control failure revealed a hazard ratio (HR) of 6.1 (95% CI: 0.7-58.2%, p = 0.05) for patients who remained similar sized after treatment for small-medium tumors. For the rest sub-groups, Cox analysis did not indicate statistical significance in any single variable. CONCLUSIONS: Height changes can be modeled by a negative exponential function for the first 7 years after treatment depending on the initial height, except for those less than 2.5 mm. Non-responding small-medium tumors multiply by 6 the probability of failure in local control.
format Online
Article
Text
id pubmed-8060957
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-80609572021-04-23 Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height Miguel, David Saornil, María Antonia de Frutos, Jesús María García-Álvarez, Ciro Alonso, Pilar Diezhandino, Patricia J Contemp Brachytherapy Original Paper PURPOSE: The aim of this study was to analyze regression rates and local control of uveal melanoma patients treated with iodine-125 ((125)I) brachytherapy based on initial tumor apical height. MATERIAL AND METHODS: Patients treated in a single institution from January 1(st), 1996 to 2019 with (125)I plaques (ROPES and COMS) for uveal melanoma were included in this study. Patients treated with brachytherapy for iris and those treated with transpupillary thermotherapy prior to brachytherapy were excluded. The sample was classified into 4 categories depending on initial apical tumor height (h(0)), i.e., h(0) ≤ 2.5 (small), 2.5 < h(0) ≤ 6.25 (small-medium), 6.25 < h(0) ≤ 10 (medium-large), and h(0) > 10 mm (large). Percentage of original tumor apical height (Δh) was collected during follow-ups. Patterns of regression were evaluated using linear least squares adjustments. Multivariable Cox regression were performed. RESULTS: In total, 305 patients met the inclusion criteria, and 27, 166, 100, and 13 were considered for small, small-medium, medium-large, and large categories, respectively. Median follow-up was 82.4, 56.8, 76.1, 89.1, and 100.1 months for the entire cohort and each sub-group, respectively. Pattern of decrease when h(0) ≤ 2.5 mm was not detectable. For the rest sub-groups, changes in height could be fitted using functional form: Δh (T) = ae(–bT) + c, R(2) ≥ 0.97. Multivariate Cox analysis factors predictive of local control failure revealed a hazard ratio (HR) of 6.1 (95% CI: 0.7-58.2%, p = 0.05) for patients who remained similar sized after treatment for small-medium tumors. For the rest sub-groups, Cox analysis did not indicate statistical significance in any single variable. CONCLUSIONS: Height changes can be modeled by a negative exponential function for the first 7 years after treatment depending on the initial height, except for those less than 2.5 mm. Non-responding small-medium tumors multiply by 6 the probability of failure in local control. Termedia Publishing House 2021-04-14 2021-04 /pmc/articles/PMC8060957/ /pubmed/33897784 http://dx.doi.org/10.5114/jcb.2021.105278 Text en Copyright © 2021 Termedia https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Miguel, David
Saornil, María Antonia
de Frutos, Jesús María
García-Álvarez, Ciro
Alonso, Pilar
Diezhandino, Patricia
Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
title Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
title_full Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
title_fullStr Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
title_full_unstemmed Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
title_short Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
title_sort regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060957/
https://www.ncbi.nlm.nih.gov/pubmed/33897784
http://dx.doi.org/10.5114/jcb.2021.105278
work_keys_str_mv AT migueldavid regressionofposterioruvealmelanomafollowingiodine125plaqueradiotherapybasedonpretreatmenttumorapicalheight
AT saornilmariaantonia regressionofposterioruvealmelanomafollowingiodine125plaqueradiotherapybasedonpretreatmenttumorapicalheight
AT defrutosjesusmaria regressionofposterioruvealmelanomafollowingiodine125plaqueradiotherapybasedonpretreatmenttumorapicalheight
AT garciaalvarezciro regressionofposterioruvealmelanomafollowingiodine125plaqueradiotherapybasedonpretreatmenttumorapicalheight
AT alonsopilar regressionofposterioruvealmelanomafollowingiodine125plaqueradiotherapybasedonpretreatmenttumorapicalheight
AT diezhandinopatricia regressionofposterioruvealmelanomafollowingiodine125plaqueradiotherapybasedonpretreatmenttumorapicalheight